Phase Ib/II Study of HCW9218, a Bifunctional TGF-ß Antagonist/IL-15 Protein Complex, for Advanced Pancreatic Cancer
Summary
The purpose of this phase I/II study is to evaluate the safety and tolerability of HCW9218 in patients with advanced pancreatic adenocarcinoma.
General Information
NCT#: NCT05304936
Study ID: HCWPAN102
Trial Phase: Phase I/II
Trial Sponsor: HCW Biologics
Therapies Used in This Trial: HCW9218